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0022-0736/© 2015 PuAn ECG-based index quantifying restitution dispersion, DRest, is evaluated in patients who experienced
Torsades de Pointes (TdP) under sotalol challenge and compared with the response in healthy subjects.
Methods and Results: ECG recordings were analyzed for quantification of DRest and QTc, among
others biomarkers. DRest provides improved discrimination following sotalol administration
between TdP and healthy subjects ([min–max]: [0.18–0.22] vs [0.02–0.12]), compared to other
biomarkers including QTc ([436–548 ms] vs [376–467 ms]). Results in healthy subjects are in
agreement with simulations of sotalol effects on a human tissue electrophysiological model.
Conclusions: This case study supports the potential of DRest for improved arrhythmia risk
stratification even with QTc values below 450 ms.
© 2015 Published by Elsevier Inc.Keywords: Rate adaptation; APD restitution; cardiotoxicity; sotalolIntroduction
Pharmacological treatment is often administered to patients
at arrhythmic risk through the use of class III anti-arrhythmic
drugs. However, in patients with a previous arrhythmogenic
substrate, class III drug-induced electrophysiological alter-
ations can sometimes worsen or even induce new arrhythmias,
such as Torsades de Pointes (TdP) [1]. Risk stratification in
patients undergoing anti-arrhythmic pharmacological treat-
ment is often performed using the surface electrocardiogram
(ECG) [2]. Within this scope, the development of specific and
selective ECG-based biomarkers for arrhythmic risk stratifi-
cation is therefore critical.
Class III anti-arrhythmic drugs, such as sotalol, block the
rapid component of the delayed rectifier current (IKr), leading
to action potential duration (APD) prolongation at the cellular
level and the resulting QT prolongation at the ECG [3]. QT
prolongation is the main biomarker used to assess drug
cardiotoxicity [2], although its main limitation is its low
specificity: neither all drugs that prolong the QT interval result
in arrhythmia, nor all pro-arrhythmic drugs prolong the QTor at: Department of Computer Science, University of
ing, Parks Road, Oxford, OX1 3QD, United Kingdom.
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blished by Elsevier Inc.interval [2,4–6], even though for the particular case of TdP
antiarrhythmic drugs many of them show QTc prolongation.
A large bodyof research has been devoted to the development
of novel ECG-based biomarkers for arrhythmic risk stratifica-
tion. Some studies have suggested that the adaptation of the QT
interval to a sudden change in heart rate can be used as a clinical
arrhythmic risk marker [7]. Moreover, prolongation of the
T-peak to T-end (Tpe) interval on the ECG, which aims to
quantify ventricular dispersion of repolarization [3], has been
associated with an increased risk of sudden cardiac death [8],
although one study showed shorter Tpe in cardiovascular patients
dying from any cause compared to the ones who survived [9].
However, the potential of these biomarkers in risk stratification
under sotalol challenge is unknown.
An additional pro-arrhythmic factor of sotalol is its
reverse use dependence, which modifies APD restitution
properties at the cellular level, increasing the slope of the
APD restitution curve [10]. The dynamic APD restitution
curve quantifies the stationary relationship between the APD
and the pacing cycle length (RR interval) at different RR
values. This sotalol-induced steeper APD restitution slope
may lead to an increased spatial dispersion of restitution
properties, which has been proposed to act as a potent
arrhythmogenic substrate, associated with the inducibility of
ventricular arrhythmias [11]. Recently, the spatial dispersion
868 A. Mincholé et al. / Journal of Electrocardiology 48 (2015) 867–873of APD restitution was successfully quantified from the ECG
by a novel index, DRest, which accounts for the rate
normalized differences of the Tpe interval under different
stationary conditions [12]. This biomarker has also been used
in previous studies and proposed as an independent predictor
of sudden cardiac death in patients with chronic heart failure
[13]. DRest has also been considered for improved discrim-
ination of patients with hypertrophic cardiomyopathy, a
genetic disease and main cause of sudden cardiac death in
patients under 35 years old [14].
The aim of this case study is to provide new evidence of the
potential of novel ECG-based biomarkers, such as DRest and
rate adaptation of QT and Tpe intervals, to improve the
stratification of patients at risk of developing drug-induced
arrhythmias. We evaluated the power of novel and established
ECG-based biomarkers to discriminate three patients who
developed TdP under sotalol challenge, with respect to healthy
volunteers who did not develop arrhythmic events.
Additionally, a computer simulation study was performed
to investigate the effect of sotalol-induced IKr block on APD
restitution dispersion. The in silico results indicate that IKr
block does not significantly increase DRest in healthy human
tissue, therefore suggesting that the increased pro-arrhythmic
risk of sotalol in patients developing TdP is likely to be caused
in synergy with their disease-related cardiac substrate.Methods
Data
Cardiotoxic effects of sotalol intake were analyzed in two
distinct groups consisting of 3 TdP patients and 25 healthy
volunteers. Due to ethical and practical constrains, data
obtained in drug-induced TdP patients are scarce but very
valuable, and they were obtained from the ECG database
available in the framework of the THEW project (University
of Rochester, ID:E-OTH-12-0006-009). The TdP patients
had a previous history of TdP and were enrolled for a
diagnostic test based on intravenous dl-sotalol IV to unmask
latent repolarization abnormalities. They experienced
drug-induced TdP after sotalol intake (2 mg/kg body
weight). To determine the ability of ECG-based biomarkers
for arrhythmic risk stratification, a subset of a second
database conducted at the Pharmacia's Clinical Research
Unit [15] was considered, consisting of 25 recordings from
healthy volunteers that were made available to us for this
study. This subset selection was based on availability of the
recordings for this particular study. The rest of the recordings
in the original database were not available for analysis, but
the 25 records were considered sufficient to be paired with
the just 3 cases of TdP patients. None of these healthy
subjects developed any arrhythmic episodes after sotalol
challenge with 160 mg of oral sotalol [15]. Seven of the
healthy subjects, who did not experience prolongation of the
QTc interval over 450 ms after the first dose, were
administered a second dose of 320 mg and hereinafter will
be referred to as “Healthy + second sotalol dose”. The
intravenous and oral doses used in our study are equivalent
based on the doses regimen approved by the US Food andDrug Administration (FDA), which suggest the replacement
of 75 mg intravenous sotalol by 80 mg oral sotalol [16].
Taking into account that the mean weight of healthy
volunteers was 74 kg [15], the intravenous dose for
160 mg oral sotalol was 2.02 mg/kg body weight, which is
equivalent to the dose administered to the TdP patients.
Moreover, at equivalent concentrations as considered in this
study, intravenous and oral sotalol have been shown to yield
similar QT and QTc effects [17].
A 12-lead ECG recording at a sampling frequency of
180 Hz was obtained from each subject. The first hour
excerpt was used for the computation of biomarkers, using
the lead with the highest signal-to-noise ratio. Other leads
were also analyzed, with no influence on the obtained results
as demonstrated in this work. ECG recordings were available
from healthy volunteers before and after drug intake, but
only after drug intake for TdP patients due to the original
definition of the clinical study.
ECG-based biomarkers
Fig. 1 illustrates the ECG biomarkers quantified in this
study. Fig. 1A shows representative simulated ECG signals
under stationary conditions for RR intervals of 1000 and
600 ms. The adaptation of the Tpe interval after a sudden
change of RR intervals from 1000 to 600 ms is shown in
Fig. 1B. Fig. 1C illustrates differences in dynamic restitution
curves due to spatial heterogeneity in repolarization in the
human ventricles. Each curve represents the stationary APD at
one ventricular location for different stationary RR intervals.
α1 and α2 denote the maximum and minimum dynamic
restitution slopes at a given RR interval. The spatial dispersion
in APD restitution slopes, DRest, is dependent on the specific
RR interval, as illustrated in Fig. 1D.
The following ECG biomarkers for drug-induced risk
stratification were computed:
- QTc (Fig. 1A): QT interval corrected by the effect of
heart rate, using Fridericia's formula (classical bio-
marker to assess cardiotoxicity).
- QT and Tpe rate adaptation t90
QT and t
90
Tpe (Fig. 1B):
time to complete 90% of the total adaptation of QT and
T
pe
intervals (respectively) after an abrupt change in
heart rate [7].
- DRest (Fig. 1D): spatial dispersion of APD restitution
slopes as illustrated in Fig. 1C. The DRest biomarker
(proposed and referred to as Δα in Ref. [12])
represents the ratio:
DRest ¼ ΔTpe
ΔRR
ð1Þ
where ΔTpe is the Tpe difference at two different RR
intervals [12]. Due to the natural beat-to-beat variabil-
ity in RR intervals, Eq. (1) is estimated with the
methodology described in [18] to avoid the need of
stationary RR segments. Therefore, in order to
properly compute DRest, long periods of time of at
least 10–15 minutes with heart rate changes present
are needed.
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Fig. 1. (A) Simulated ECGs for two RR intervals or cycle lengths (CLs) of 1000 and 600 ms under stationary conditions. (B) Response of the Tpe interval after a
change in the RR interval from 1000 to 600 ms, and illustration of t90
Tpe computation. (C) Restitution curves corresponding to different spatial locations in the
heart. Each curve represents the APD at different stationary RR intervals. α1 and α2 represent themaximum andminimum slopes for RR = 600 ms. (D) Difference
between maximum and minimum restitution slopes, DRest, computed for a range of RR intervals.
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APD restitution
An in silico simulation study was conducted to simulate the
effect of sotalol-induced Ikr block on dispersion of repolari-
zation in healthy human ventricular substrates. Propagation of
electrical excitation was simulated through a transmural
ventricular slice of human tissue, as described in Ref. [12].
The well-established human ten Tusscher–Panfilov action
potential model [19], which provides a good characterization
of human APD restitution dynamics, was used to represent
membrane dynamics. The stimulation protocol, activation
sequence and transmural heterogeneities were defined as
reported in Ref. [12]. The effects of sotalol were simulated for
an IC50 dose, resulting in a 50% reduction in IKr conductance.
Spatial dispersion of APD restitution was quantified in the
simulations by computing the derivative of the curve that
relates each stationary Tpe with respect to the corresponding
stationary RR. The range of simulated RR intervals was from
500 to 1500 ms.
Results
Risk stratification of ECG-based biomarkers
Fig. 2 presents the different ECG-based biomarkers
quantified in this case study, plotted against the mean RR
interval for each subject. Results are provided after sotalol
administration for TdP patients, and before and after sotalol
intake for healthy volunteers. DRest shows the best discrim-
ination power between both population groups (Fig. 2A).These results highlight that TdP patients exhibit much larger
DRest values than any of the healthy subjects, either before or
after equivalent sotalol intake. Significant differences between
the healthy group with the first dose and the TdP groups after
sotalol intake were observed for DRest with a p-value of 0.006
when the non-parametric Mann–Whitney U test was per-
formed. Importantly, 160 mg sotalol administration does not
significantly increase dispersion of APD restitution DRest in
the healthy subgroup (p-value = 0.27). Moreover, DRest for
all TdP patients lay beyond six standard deviations of themean
DRest value of healthy volunteers.
For comparison purposes, data for the commonly used
biomarker of drug cardiotoxicity QTc are also presented
(Fig. 2B). Sotalol administration (160 mg) only led to a slight
increase in QTc (about 10 ms in mean) in the healthy group.
Although 2 TdP patients showed marked QTc prolongation,
the third TdP patient exhibited a similar QTc as those in the
non-inducible TdP healthy cohort. When compared to DRest,
less significant differences were found (p-value = 0.009)
when the Mann–Whitney U test was performed.
When performing other standard tests as the Student's t
test (assuming unequal variances and unequal sample
size) to evaluate the differences in DRest and QTc
between TdP and healthy volunteers (160 mg sotalol ad-
ministration), statistically significant differences were
observed in DRest (p-value =0.0013), while for QTc,
the p-value was 0.1318. Similar results were obtained
when applying other QT correction formulas, such as
Bazett's, which also resulted in QTc failing to provide a
complete separation between groups.
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Fig. 2. Quantification of ECG-based biomarkers for TdP patients after sotalol challenge (filled diamonds), and healthy volunteers before (open circles), afte
sotalol administration (gray squares) and after the second sotalol dose (filled triangles). (A and B) Rate adaptation biomarkers of Tpe and QT intervals (t90
Tpe and
t90
QT, respectively). (C) Results corresponding to the biomarker DRest, quantifying dispersion of APD restitution. (D) Results for the QTc interval.
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of the Tpe (t90
Tpe) and QT (t90
QT) intervals are shown in
Fig. 2C and D. A large variability is observed within the
healthy group in terms of rate adaptation times (both before
and after 160 mg sotalol intake), with differences over 150
and 100 s for Tpe and QT adaptation, respectively. The rate
adaptation biomarkers show values for TdP patients within
the upper range obtained for healthy subjects.
Regarding the second 320 mg sotalol dose given to seven
healthy subjects, results on DRest, QTc, and t90 values of Tpe
and QT adaptation are in the same range as for the previous
160 mg dose in healthy subjects. This is further supported in
Table 1, which summarizes the results presented in Fig. 2 for the
different ECG-based biomarkers as well as Tpec, representing
the Tpe interval corrected by the effect of heart rate using
Fridericia's formula. Results are presented as 20 and 80
percentiles bounds in the healthy and healthy + sotalol groups
to avoid possible outliers, the full range for healthy sub-
jects + second sotalol dose, and individual values for the three
TdP patients. We cannot detect electrophysiological abnormal-Table 1
[20 Percentile–80 percentile] bounds for the different ECG biomarkers in healthy subjects before and after sotalol intake, whole range of healthy subjects afte
second sotalol dose, and values for the three sotalol-induced TdP patients (TdP1, TdP2 and TdP3).
RR [ms] DRest QTc [ms] t90
Tpe [s] t90
QT [s] Tpec [ms
Healthy 776–925 0.025–0.058 384–407 77–227 86–200 82–98
Healthy + Sotalol 815.8–951 0.033–0.054 394–424 93–259 104–210 83–96
Healthy + 2nd dose 840–1100 0.029–0.068 384–427 92–247 122–243 69–102
TdP1 + Sotalol 944.6 0.22 548 292 285 116
TdP2 + Sotalol 1158.1 0.18 436 268 267 77
TdP3 + Sotalol 902.3 0.21 480 251 285 107
Biomarkers analyzed were dispersion of APD restitution (DRest), QTc, the rate adaptation times of QT and Tpe intervals (t90
Tpe and t90
QT) and Tpec.rities in the TdP patients in time interval-based biomarkers such
as Tpe and RR intervals, as they present values within normal
ranges and no significant differences were found.
t90, QTc and DRest were computed using the ECG lead
with the highest signal-to-noise ratio, which in this study are
V2, V3 or V4. In order to evaluate whether these results
depend on the lead selection, Fig. 3 shows the values of the
biomarkers DRest and QTc for leads V2 to V4 (the ones that
have better delineation of the Tpe interval). This figure shows
that our results are consistent across leads and therefore that the
lead selection does not affect the main conclusions of
this study.Role of IKr block in determining sotalol-induced changes in
APD restitution dispersion
Computer simulations were conducted to investigate the
effect of sotalol-induced IKr block in the biomarker DRest
under non-diseased conditions. The aim was to help in the
interpretation of the results obtained for healthy volunteers, byr
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Fig. 3. Sensitivity of DRest and QTc biomarkers with respect to V2–V4 leads.
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(if delineation can be successfully performed).
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the presence of an additional cardiac disease-related substrate.
Fig. 4 presents the simulation results for the biomarker
DRest in control conditions (blue solid line) and for 50% IKr
block (red dashed line). The in silico results support that IKr
block can actively modulate the pro-arrhythmic substrate,
increasing APD restitution dispersion at fast pacings.
However, these differences are hardly noticeable for RR
intervals above 800 ms. The simulation results are hence in
agreement with the ECG analysis presented in Fig. 2A,
showing similar values in DRest before and after sotalol
administration for healthy subjects, as most of them presented
RR intervals above 800 ms.Discussion
In this study, we evaluated the potential of novel and
established rate dependent ECG-based biomarkers for the
stratification of 3 TdP patients against a cohort of healthy
volunteers following sotalol administration. For the three
patients who developed TdP after sotalol administration,
increased APD restitution dispersion (quantified by DRest)
was observed and shown to provide the best discriminationD
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Fig. 4. Simulated DRest measured in a human 2D tissue preparation in
control (black, solid line) and under 50% IKr block (gray, dashed line),
mimicking the effect of sotalol.with respect to the healthy group, compared to other biomarkers
including QTc. Computer simulation results show agreement
with the observations of DRest in healthy volunteers, and they
suggest that IKr block per se does not cause alterations of DRest
in a healthy substrate.
Two different rate dependencies have been considered in this
study. Firstly, a “short time” rate dependency or adaptation,
which is in the very core definition of some of the analysed
biomarkers. Thus, t90 values represent the rate adaptations of the
QT and Tpe intervals to changes of heart rate, as computed in
reference [18]. Rate adaptation of Tpe is also used in the
computation ofDRest to remove thememory effect betweenTpe
and RR intervals. This memory compensation is described in
detail in Ref. [18]. Secondly, another “long term” rate
dependency was considered by representing biomarkers against
mean RR values of each analysed ECG excerpt. In normal
conditions DRest is higher for shorter RR intervals [12]. In this
study, as the RR intervals of the subjects are between 750 and
1100 ms, differences between DRest values are expected to be
around 0.02 (as evidenced in Ref. [12] and in simulations shown
in Fig. 4). Therefore, the larger differences in DRest found
between healthy subjects andTdP patients (around 0.15), are not
accounted for the RR dependency or the inter subject variability
for healthy volunteers.ECG quantification of APD restitution dispersion
Healthy subjects did not present differences in DRest after
sotalol intake, whereas all patients developing sotalol-induced
TdP exhibited substantially higher DRest values compared to
the healthy group.
Large restitution gradients (DRest ~0.2) were observed in
the 3 patients developing TdP under sotalol challenge. This
is in agreement with previous studies showing correlation
between increased APD restitution dispersion and a higher
inducibility of ventricular tachyarrhythmias [11]. These
values are in fact considerably larger than those shown in
healthy volunteers in our study and also previously reported
DRest magnitudes in other cohorts of patients at high
arrhythmic risk in the absence of sotalol. A recent study
considering ECG recordings from patients with chronic heart
failure has reported DRest values from non-sudden cardiac
death victims of 0.026 ± 0.003 and from SCD victims of
0.052 ± 0.013 [13]. An additional study on hypertrophic
cardiomyopathy patients [14] has reported DRest values of
around 0.065. The remarkable differences with the sotalol-
induced TdP patients analyzed in this study suggest an active
modulation by sotalol of the underlying pro-arrhythmic
substrate, which can be quantified from the body-surface
ECG by means of the DRest biomarker. Therefore, the DRest
values found in patients with a pro-arrhythmic substrate in
previous studies (in the absence of sotalol) are substantially
smaller than those obtained in the TdP patients following
sotalol administration in our case study (DRest of around 0.2).
Simulation results presented in Fig. 4 indicate that IKr
block does not significantly increase DRest in healthy human
tissue, in agreement with the ECG analysis results obtained
from the healthy subjects. Indeed, when increasing the dose
to 320 mg oral sotalol, DRest values did not alter with
872 A. Mincholé et al. / Journal of Electrocardiology 48 (2015) 867–873respect to before and after 160 mg oral sotalol intake. These
results suggest that the increased pro-arrhythmic risk of sotalol
in patients developing TdP is likely to be caused by synergistic
effects of sotalol and their disease-related cardiac substrate.
Rate adaptation of the QT and Tpe intervals
Within the group of healthy volunteers who did not
develop arrhythmias after sotalol administration, rate
adaptation of the QT and Tpe intervals was not significantly
affected by sotalol administration (see Fig. 2C and D).
However, a prominent variability was observed in these
biomarkers, over 100 s in the healthy group (see Table 1).
This variability may be due to the dependence of rate
adaptation on the initial RR interval and the change in RR
interval, which are different for each ECG recording.
For the three patients who developed TdP, rate adaptation
times t90 for QT and Tpe show moderately high values,
although in the range of the healthy group. Previous studies
have shown a more clear association between slow rate
adaptation of repolarization and a higher propensity of
suffering life-threatening arrhythmias [7].
Limitations and further studies
We present the results of this study as a case report, given
the small number of available data for patients developing
TdP after sotalol administration. The absence of ECG
recordings prior to drug intake in these patients and the lack
of a common disease condition in this group, also hamper
our ability to ascertain whether DRest represents a measure
of the baseline pro-arrhythmic substrate or this substrate
develops dynamically after IKr blockade. In spite of these
limitations, this case study provides additional evidence on
the potential of DRest for arrhythmic risk stratification by
demonstrating an improved performance for discrimination
with respect to the classical QTc, and supporting the need to
evaluate the novel biomarker in further studies. Computing
DRest requires the presence of heart rate changes over long
periods of time. This represents an additional requirement
with respect to other biomarkers such as QTc, and the
acquisition of ECG recordings needs to be designed
appropriately to be able to compute DRest. To the best of
our knowledge, additional recordings are not easily acces-
sible at present, and therefore we present our findings in the
form of a case report supporting DRest as a potentially useful
biomarker to take into consideration in future studies.
The evidence presented in this case study therefore
encourages the design of future studies including long ECG
recordings in the presence of heart rate changes, from
patients treated with sotalol or patients with a previous
history of TdP, who do and do not develop TdP under
pharmacological challenge.Conclusion
In summary, the present case study presents evidence for
restitution dispersion, evaluated from the ECG using the
index DRest, as a promising biomarker for pro-arrhythmia
stratification. In this dataset, DRest exhibited clear discrim-ination between TdP patients and healthy volunteers, even
for the TdP patient with a normal QTc value of 436 ms. This
suggests that DRest could be used to identify patients at high
risk of developing TdP, even with a normal QTc. The results
therefore point toward a promising potential for DRest,
worth exploring in larger studies to allow for a more
thorough comparison with other biomarkers.Acknowledgments
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